OncoMed Presents New Data For Vantictumab At European Cancer Congress

(RTTNews) - OncoMed Pharmaceuticals, Inc. (OMED) announced new data for vantictumab, a monoclonal antibody targeting the WNT pathway, at a poster session at the Joint ECCO 17, 38th ESMO and 32nd ESTRO European Cancer Congress 2013 in Amsterdam, The Netherlands.

The company noted that, in the ongoing Phase 1a clinical trial, 29 patients with advanced and refractory solid tumors were treated with single-agent vantictumab. To date the drug candidate has been well tolerated up to the current dose of 15 mg/kg every three weeks.

Based on these clinical results and data from preclinical patient-derived tumor models, OncoMed is initiating Phase 1b clinical trials in three tumor indications to study its safety in combination with standard-of-care chemotherapy.